1. Home
  2. DNUT vs RGNX Comparison

DNUT vs RGNX Comparison

Compare DNUT & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krispy Kreme Inc.

DNUT

Krispy Kreme Inc.

HOLD

Current Price

$3.65

Market Cap

660.4M

ML Signal

HOLD

Logo REGENXBIO Inc.

RGNX

REGENXBIO Inc.

HOLD

Current Price

$13.62

Market Cap

761.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNUT
RGNX
Founded
1937
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
660.4M
761.9M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
DNUT
RGNX
Price
$3.65
$13.62
Analyst Decision
Buy
Strong Buy
Analyst Count
6
9
Target Price
$6.22
$30.78
AVG Volume (30 Days)
2.4M
696.9K
Earning Date
02-24-2026
11-06-2025
Dividend Yield
1.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,534,272,000.00
$161,318,000.00
Revenue This Year
N/A
$133.58
Revenue Next Year
$0.19
$45.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
91.30
52 Week Low
$2.50
$5.04
52 Week High
$9.56
$15.84

Technical Indicators

Market Signals
Indicator
DNUT
RGNX
Relative Strength Index (RSI) 34.87 46.45
Support Level $4.12 $14.53
Resistance Level $4.49 $15.31
Average True Range (ATR) 0.22 0.89
MACD -0.07 -0.13
Stochastic Oscillator 3.30 24.58

Price Performance

Historical Comparison
DNUT
RGNX

About DNUT Krispy Kreme Inc.

Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Share on Social Networks: